Trials / Unknown
UnknownNCT03594656
Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease
Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 288 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Lingzhi(Ganoderma) is widely used in traditional Chinese medicine. Previous studies indicated that Lingzhi was safe, well tolorated, and improved symptoms as an add-on therapy to levodopa in early Parkinson's disease(PD) patients. Here the investigators design a multicenter, randomized, double-blind, placebo-controlled, delayed-start trial to evaluate the effects of Lingzhi on modifying disease progression in untreated PD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ganoderma | 0.8g twice daily |
| DRUG | Placebos | 0.8g twice daily |
Timeline
- Start date
- 2018-07-15
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2018-07-20
- Last updated
- 2021-08-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03594656. Inclusion in this directory is not an endorsement.